

Dr. Eric Abadie
European Medicines Agency (EMA)
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

28 May 2009

Subject: Withdrawal of Biferonex (interferon beta 1a), EMA/H/C/901

Dear Dr. Abadie

BioPartners GmbH would like to inform you that at this point in time, the decision was taken to withdraw the application for Marketing Authorisation of Biferonex (interferon beta 1a), 6 MIU, solution for injection, prefilled syringes.

The withdrawal of application for Biferonex was based on the following reason:

- The CHMP considers that the additional information provided in support of the re-examination does not allow the Committee to change their view about the benefit-risk balance of Biferonex in the treatment of patients with relapsing-remitting multiple sclerosis.

At the moment being, there are no ongoing clinical trials or compassionate use programs with Biferonex.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

We agree for this letter to be published on the EMA website.